Literature DB >> 7497754

Hemorrhagic complications of thrombolytic therapy.

J E Lauer1, J J Heger, M J Mirro.   

Abstract

Thrombolytic therapy salvages ischemic myocardium by rapidly reestablishing coronary artery patency in acute myocardial infarction. One of its major limitations is the complication of hemorrhage. A retrospective study of myocardial infarction patients who received thrombolytic therapy was performed to determine risk factors associated with a hemorrhagic event. Three hundred fifty patients were enrolled, and 20 (5.7%) had a bleeding complication, including four patients (1.1%) who had an intracranial hemorrhage. The factors associated with an increased risk for a significant hemorrhagic event were age (> 65 years) and female gender. Factors associated with an intracranial hemorrhage were age (> 65 years) and a history of hypertension.

Entities:  

Mesh:

Year:  1995        PMID: 7497754     DOI: 10.1378/chest.108.6.1520

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice.

Authors:  Kathleen A Stringer; Meghan Tobias; John S Dunn; Jackie Campos; Zachary Van Rheen; Mitra Mosharraf; Rajiv Nayar
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-07-29       Impact factor: 2.557

2.  Pulmonary haemorrhage following thrombolysis with streptokinase in myocardial infarction.

Authors:  Krishna Prasad; Parminder Singh; Kewal Kanabar; Rajesh Vijayvergiya
Journal:  BMJ Case Rep       Date:  2020-01-23

3.  Lingual Haematoma due to Tenecteplase in a Patient with Acute Myocardial Infarction.

Authors:  Muhlis Bal; Yavuz Atar; Ziya Salturk; Ahmet Hakan Ateş; Serkan Yağcı; Gökçen Coşkun Bal
Journal:  Case Rep Otolaryngol       Date:  2013-06-03

4.  Splenic rupture following thrombolysis treatment for acute myocardial infarction.

Authors:  Rl Harries; Kf Gomez
Journal:  J Surg Case Rep       Date:  2012-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.